Department of Laboratory Medicine, Microbiology Service, Cliniques universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium.
Department of Laboratory Medicine, Microbiology Service, Cliniques universitaires Saint-Luc and Université Catholique de Louvain, Brussels, Belgium; Scientific Research Pole of Medical Microbiology, Institute of Experimental and Clinical Research, Université Catholique de Louvain, Brussels, Belgium.
J Virol Methods. 2021 Jun;292:114129. doi: 10.1016/j.jviromet.2021.114129. Epub 2021 Mar 18.
At present, the only reliable test for COVID-19 diagnosis is RT-qPCR. Serological assays have been widely used to increase the detection sensitivity of infected population. Hereby, we report the performance of a new pan-IgG multiplex Enzyme Immunoassay (immunodot) method for exploration of discrepant SARS-COV-2 serological results.
A retrospective study on 38 residual serum samples from recovered COVID-19 subjects with discordant serological results on Roche and Snibe platforms, were reanalyzed on a new semi-automated pan-IgG immunodot Enzyme Immunoassay, namely COVIDOT-TEST, in order to find the source of discrepancies and to evaluate the latter method. All samples were analyzed on the BlueDiver® Instrument and all strips were read by the BlueScan® Scanner using Dr DOT® Software.
Based on our data, subject samples showed specific IgG reactions on ≥ 2 different antigens on immunodot strips. Of these 38 samples, 97.4 % of samples showed specific IgG reaction against S1 + S2 antigens, 89.5 % showed against RBD antigen, 86.8 % against S2 antigen reaction on the COVIDOT-TEST kit. Specific IgG-S1 antigen and IgG-N antigen reactions were detected in 73.7 % and 65.8 % of the samples, respectively.
The new semi-automated pan-IgG immunodot Enzyme Immunoassay method appeared to be a reliable assay to confirm suspicious COVID-19 serological screening results.
目前，COVID-19 诊断的唯一可靠检测方法是 RT-qPCR。血清学检测已被广泛用于提高感染人群的检测灵敏度。在此，我们报告了一种新的 pan-IgG 多重酶免疫吸附测定（免疫斑点）方法用于探索 SARS-COV-2 血清学结果不一致的性能。
对罗氏和新柏平台检测结果不一致的 38 例康复 COVID-19 患者的残留血清样本进行回顾性研究，在新的半自动化 pan-IgG 免疫斑点酶免疫吸附测定（COVIDOT-TEST）上重新分析，以寻找差异的来源并评估后者方法。所有样本均在 BlueDiver®仪器上进行分析，所有条带均使用 BlueScan®扫描仪和 Dr DOT®软件进行读取。
根据我们的数据，受试者样本在免疫斑点条上显示出针对≥2 种不同抗原的特异性 IgG 反应。在这 38 个样本中，97.4%的样本对 S1+S2 抗原显示出特异性 IgG 反应，89.5%对 RBD 抗原，86.8%对 COVIDOT-TEST 试剂盒的 S2 抗原显示出特异性 IgG 反应。分别在 73.7%和 65.8%的样本中检测到特异性 IgG-S1 抗原和 IgG-N 抗原反应。
新的半自动化 pan-IgG 免疫斑点酶免疫吸附测定方法似乎是一种可靠的方法，可用于确认可疑的 COVID-19 血清学筛查结果。
